Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CROHN'S DISEASE Clear all
Terminated Phase 3 Interventional Results available

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

NCT01190839
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab, Placebo
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
62
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT04673357
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Not applicable Interventional

The Impact of Time Restricted Feeding in Crohn's Disease

NCT04271748
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Time Restricted Feeding
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional Results available

Crohn's Allogeneic Transplant Study

NCT01570348
View directory record Official record
Conditions
Crohn Disease
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Mycophenolic Acid, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 11, 2026, 9:37 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

NCT06637631
View directory record Official record
Conditions
Crohn's Disease
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

NCT04173273
View directory record Official record
Conditions
Crohn's Disease
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
192
States / cities
Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated Phase 4 Interventional Results available

Trial of High Dose Vitamin D in Patient's With Crohn's Disease

NCT02208310
View directory record Official record
Conditions
Crohn's Disease, Vitamin D Deficiency
Interventions
Cholecalciferol 10,000 IU, Cholecalciferol 400 IU
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated No phase listed Observational

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

NCT01582568
View directory record Official record
Conditions
Crohns Disease
Interventions
Certolizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 11, 2026, 9:37 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

NCT03992469
View directory record Official record
Conditions
Crohn's Disease
Interventions
EBFAHF-2, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ImmuneSense™ IBD Study

NCT05769829
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Hialeah, Florida • Miami, Florida • Uniontown, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Not applicable Interventional

Effect of Grapes in Inflammatory Bowel Disease

NCT05972694
View directory record Official record
Conditions
Crohn Disease
Interventions
Freeze dried grape powder
Dietary Supplement
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Not applicable Interventional

CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease

NCT05034159
View directory record Official record
Conditions
Crohn Disease, Insomnia, Sleep Disturbance, Pain, Inflammation
Interventions
Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

NCT03870334
View directory record Official record
Conditions
Crohn's Disease
Interventions
BT-11 880 mg, Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 11, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099
View directory record Official record
Conditions
Crohn Disease
Interventions
LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 11, 2026, 9:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)

NCT01169194
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Recruiting Phase 1 Interventional

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT03816345
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions
Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
51
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NCT06045754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, Adalimumab, Ustekinumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Active, not recruiting No phase listed Observational

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

NCT03251118
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
37
States / cities
Lancaster, California • Mission Hills, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 11, 2026, 9:37 AM EDT
Withdrawn Phase 3 Interventional

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

NCT01674413
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Adalimumab PRN, Placebo
Drug
Lead sponsor
Peter Higgins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 11, 2026, 9:37 AM EDT
Withdrawn Phase 2 Interventional

Immune Ablation and Stem Cell Support for Crohn's Disease

NCT00179842
View directory record Official record
Conditions
Crohn Disease
Interventions
Stem Cell Transplant
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 11, 2026, 9:37 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Corticosteroid Dosage for Crohn's Disease Flare

NCT02392286
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Corticosteroid
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)

NCT00950105
View directory record Official record
Conditions
Crohn's Disease
Interventions
CPSI-2364 or placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 11, 2026, 9:37 AM EDT
Completed Not applicable Interventional

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

NCT04147585
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions
Intermittent Reduced Calorie Diet (IRCD)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 11, 2026, 9:37 AM EDT